Agenda

Return

C. 38

To:	Board of Supervisors
From:	Anna Roth, Health Services Director
Date:	October 16, 2018

Contra

Costa

County

Subject:

Purchase Order with Polymedco, Inc.

APPROVE	OTHER
RECOMMENDATION OF CNTY ADMINISTRATOR	RECOMMENDATION OF BOARD COMMITTEE

Action of Board On: 10/16/2018

APPROVED AS RECOMMENDED

OTHER

Clerks Notes:

VOTE OF SUPERVISORS

AYE:

John Gioia, District I Supervisor
Candace Andersen, District II Supervisor
Diane Burgis, District III Supervisor
Karen Mitchoff, District IV Supervisor
Federal D. Glover, District V Supervisor

Contact:	Jaspreet Benepal, 925-370-5101
cc:	Tasha Scott Marcy Wilhelm Margaret Harris

I hereby certify that this is a true and correct copy of an action taken and entered on the minutes of the Board of Supervisors on the date shown.
ATTESTED: October 16, 2018
David Twa,

BY:	, Deputy

RECOMMENDATION(S):

APPROVE and AUTHORIZE the Purchasing Agent to execute, on behalf of the Health Services Director, an amendment to Purchase Order #F01880 with Polymedco, Inc., to increase the payment limit by $300,000 to a new payment limit of $780,000 for reagents and supplies to perform immunochemical fecal occult blood testing for the Clinical Laboratory at Contra Costa Regional Medical Center (CCRMC), with no change in the original term of September 1, 2015 through August 31, 2019.

FISCAL IMPACT:

100% Hospital Enterprise Fund I Budget.

BACKGROUND:

Polymedco’s OC-Auto Micro 80 Analyzer with fecal occult blood (FOB) reagents is an automated immunochemical FOB testing system that detects human red cells only with no interferences from red meat, turnips, melons, aspirin, anti-inflammatory drugs and vitamin C. This improvement directs many more of the “right” patients to colonoscopy leading to the earlier detection of polyps and colorectal cancer. The Laboratory is sending greater quantities of the cancer detection test to patients in an effort to get more people to return them and be screened.

CONSEQUENCE OF NEGATIVE ACTION:

If this Purchase Order is not approved, the CCRMC Clinical Laboratory will not be able to perform patient testing for colorectal cancer.